Purpose: To determine whether bevacizumab may improve anatomic and visual outcomes in patients with ocular ischemic syndrome (OIS).
Design: Interventional case reports.
Methods: Two patients with OIS presenting with unilateral ocular pain, iris neovascularization, and macular edema. Intravitreal injection of bevacizumab (1.25 mg). The main outcome measures were postinjection best-corrected visual acuity (BCVA), intraocular pressure (IOP), angiographic findings, and optical coherence tomography (OCT) findings and complications.
Results: One week after treatment, both patients demonstrated regression of the iris neovascularization and improvement of the macular edema, with no changes in BCVA and IOP. One eye was reinjected at four months. After three and seven months, no significant or systemic adverse events were observed, and no signs of new iris neovascularization were present.
Conclusions: Intravitreal bevacizumab may be useful for the treatment of eyes with iris neovascularization and macular edema secondary to OIS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajo.2007.02.037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neovascular Glaucoma as the First Symptom of Bilateral Occlusive Retinal Vasculitis in a 4-Year-Old Girl: A Case Report.
Biomedicines
January 2025
Department of the Pediatric Ophthalmology, Children's Memorial Health Institute, 04-730 Warsaw, Poland.
Neovascular glaucoma is a rare and serious condition typically associated with advanced ocular or systemic vascular diseases such as central retinal vein occlusion or diabetic retinopathy. This report describes a unique case of neovascular glaucoma presenting for the first time as an initial symptom of bilateral occlusive retinal vasculitis (ORV) in a generally healthy 4-year-old girl. The patient presented with symptoms of pain and redness in the left eye, accompanied by high intraocular pressure.
View Article and Find Full Text PDFAn Atypical Finding of Peripheral Retinal Ischemia and Neovascularization in Neurofibromatosis Type 1: A Case Report.
Cureus
December 2024
Radiology Department, King Khaled Eye Specialist Hospital, Riyadh, SAU.
Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic multisystem phakomatosis that can affect the skin, bones, and nervous system. NF1 typically presents with skin lesions, including freckles, café-au-lait macules, plexiform neurofibromas, and bony dysplasia, and is usually accompanied by a family history of the disorder. Ocular manifestations vary, but iris Lisch nodules and optic nerve gliomas are the most common features.
View Article and Find Full Text PDFResolution of Anterior Uveal Infiltration of Acute Lymphoblastic Leukemia After Chimeric Antigen Receptor T-Cell Therapy.
J Vitreoretin Dis
August 2024
University Hospitals Eye Institute, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
To present a case of acute B-cell lymphoblastic leukemia (B-ALL) ocular relapse treated with chimeric antigen receptor T-cell (CAR T) therapy. A retrospective case review was evaluated. A 69-year-old woman with a history of BALL presented with bilateral hypopyons and 3+ anterior chamber cells that responded to topical prednisolone.
View Article and Find Full Text PDFAnterior segment ischaemia following insertion of a PreserFlo Micro-Shunt with mitomycin-C for uncontrolled open angle glaucoma.
BMJ Case Rep
November 2024
Ophthalmology, University Hospitals of Leicester NHS Trust, Leicester, UK.
To our knowledge, this is the first report of anterior segment ischaemia after PreserFlo Micro-Shunt insertion surgery. Our patient developed anterior chamber (AC) activity and keratic precipitates 1 week after surgery. Five weeks after surgery, examination revealed a shallow AC, a distorted pupil with posterior synechiae and surface iris neovascularisation.
View Article and Find Full Text PDFEarly Versus Delayed Vitrectomy for Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy.
Am J Ophthalmol
February 2025
From the Moorfields Eye Hospital NHS Foundation Trust (R.A., P.S., N.S., S.A., A.R., J.R., S.S., L.W.), London, UK.
Article Synopsis
- - This study compares the outcomes of early versus delayed pars plana vitrectomy (PPV) in patients experiencing their first vitreous hemorrhage (VH) due to proliferative diabetic retinopathy (PDR) at Moorfields Eye Hospital from 2014 to 2016, excluding patients with specific eye conditions.
- - Patients were categorized into two groups: early PPV (within 6 weeks) and delayed PPV (after 6 weeks), with data collected on visual acuity and complications at baseline and 12 months post-surgery.
- - Results indicated that the early PPV group had significantly better visual acuity and fewer serious complications compared to the delayed group, highlighting the benefits of earlier intervention.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!